Memocal 40 CM Solution for Injection

Summary of Product characteristics

                                Revised: October 2012
AN: 00838/2012
SUMMARY OF PRODUCTS CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Memocal 40 CM Solution for Injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Calcium Borogluconate 40% CM contains Calcium Borogluconate 40% w/v
and Magnesium Hypophosphite Hexahydrate 5% w/v.
Each 400ml contains:
11.9g calcium (provided by calcium gluconate and calcium
borogluconate)
and
1.85g magnesium (provided by magnesium hypophosphite).
Also contains 6.48% w/v Boric Acid
EXCIPIENTS:
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection
A clear pale yellow solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Memocal 40 CM Solution for Injection is indicated in the treatment of
hypocalcaemia in cattle where increased blood magnesium levels are
required
4.3
CONTRAINDICATIONS
None
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
Page 1 of 4
Revised: October 2012
AN: 00838/2012
4.5 SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
The solution should be warmed to body temperature before
administration. Intravenous injections should be given slowly in
order to avoid possible neuromuscular dysfunction and cardiac
insufficiency. Normal aseptic precautions should be observed.
Sites of subcutaneous administration should be massaged gently.
ii. Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Care should be taken to avoid accidental self injection; may cause
irritation at the site of injection.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Occasional temporary swelling may occurs at sites of subcutaneous
administration
4.7 USE DURING PREGNANCY, LACTATION OR LAY
Memocal 40 CM Solution for Injection is safe for use during pregnancy
and lactation.
4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None
4.9 AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
Administer by subcutaneou
                                
                                Read the complete document